<?xml version="1.0" encoding="UTF-8"?>
<p>Thus, in cardiovascular disease there exists an imbalance between increased RAS activation and reduced ACE2 counter-regulatory effects (
 <xref ref-type="fig" rid="F3">figure 3</xref>), which may render subjects with increased cardiovascular risk burden susceptible to conditions that worsen asymmetries in RAS/ACE2.
</p>
